Correspondence
Vision 1 Year after Gene Therapy for Leber's Congenital Amaurosis
N Engl J Med 2009; 361:725-727August 13, 2009
- Article
To the Editor:
Video
Fixation Data at 1 Month and 12 Months after Treatment
Leber's congenital amaurosis, a common cause of blindness in infants and children,1 recently became the first human genetic retinal disease to show improved vision in response to treatment. Patients with mutations in the gene encoding retinal pigment epithelium–specific 65-kD protein (RPE65) had gains in vision within weeks after subretinal injection of a vector containing the gene in one eye.2-5 At 1-year follow-up after gene therapy, the three young adult patients in our trial4,5 remained without serious adverse events.
A noteworthy observation in one patient at 1 year after treatment prompted further studies. For the first time in her life, the patient reported that she could read the illuminated numerical clock display on the dashboard of the family vehicle while she was sitting in the front seat. The numerals subtended a visual angle equivalent to a visual acuity of 20/200, which is not different from her formally measured visual acuities at baseline or at 1 year after treatment. The simplest explanation of this development would be increased visual sensitivity either at the fovea or in the treated region of the superotemporal retina. However, visual sensitivity (measured by means of microperimetry) was unchanged at this visit as compared with earlier post-treatment visits (Figure 1AFigure 1
Slow Emergence of a Pseudo-Fovea within the Treated Retinal Region and Perception of Previously Unseen Stimuli.).We sought to determine the basis of this development by quantifying fixation of the patient's gaze to dim targets over a range of luminances straddling her perception. At baseline, the patient had foveal fixation in both eyes over a range of target luminances from 2.1 to 2.7 log10 units higher than the normal foveal perceptual threshold (Figure 1B), and the results were like those of other patients with Leber's congenital amaurosis caused by RPE65 mutations and similar visual-acuity levels.5
Fixation dwell time, quantified along the diagonal meridian with a range of target luminances perceived by the patient, suggested a slow emergence of visual gain over many months causing progressively greater fixational use of the treated superotemporal retina (Figure 1B). This gain was particularly evident at lower luminances. By 12 months after treatment, the patient reported perception of the lowest luminance target (1.8 log10) for the first time. This target was not seen during any previous visit. New perception was accompanied by a distinct shift in fixation into the treated superotemporal retina (Figure 1C, video, and the Supplementary Appendix, available with the full text of this letter at NEJM.org). Cone sensitivities in the control and study eyes of the patient were rendered as three-dimensional images on the view of the ocular fundus with a superimposed circular grid (Figure 1 in the Supplementary Appendix). Foveal sensitivities in the two eyes were similar, but the superotemporal region of the treated eye, the “pseudo-fovea,” was remarkably different from the cone blindness in the comparable region of the control eye.
The change in fixation by the patient was driven by the treatment-created extrafoveal cone vision with better sensitivity and greater expanse than the untreated foveal region (Figure 1 in the Supplementary Appendix).4,5 The unexpected late emergence of visual gain in the patient to spatially coded and sustained stimuli and a coincident change in preference for fixation from the fovea to the treated retinal region suggest a slow development of a pseudo-fovea and an underlying experience-dependent plasticity of the adult visual system. These results raise the possibility that this gene-based therapy may further improve visual function in an unexpected and useful way in previously untreatable congenital blindness.
Artur V. Cideciyan, Ph.D.
University of Pennsylvania, Philadelphia, PA
cideciya@mail.med. upenn. edu William W. Hauswirth, Ph.D.
University of Florida, Gainesville, FLTomas S. Aleman, M.D.
University of Pennsylvania, Philadelphia, PAShalesh Kaushal, M.D., Ph.D.
University of Florida, Gainesville, FLSharon B. Schwartz, M.S., C.G.C.
University of Pennsylvania, Philadelphia, PASanford L. Boye, M.Sc.
University of Florida, Gainesville, FLElizabeth A.M. Windsor, B.Sc.
University of Pennsylvania, Philadelphia, PAThomas J. Conlon, Ph.D.
University of Florida, Gainesville, FLAlexander Sumaroka, Ph.D.
Alejandro J. Roman, M.Sc.
University of Pennsylvania, Philadelphia, PABarry J. Byrne, M.D., Ph.D.
University of Florida, Gainesville, FLSamuel G. Jacobson, M.D., Ph.D.
University of Pennsylvania, Philadelphia, PASupported by a grant from the National Eye Institute of the National Institutes of Health, Department of Health and Human Services (U10 EY017280).
Drs. Byrne and Hauswirth report having a financial interest in the use of adeno-associated virus (AAV) therapies and owning equity in Applied Genetics Technologies, a company that might, in the future, commercialize some aspects of this work; Dr. Kaushal, serving as a principal investigator of a clinical trial of AAV-RPE65 to treat Leber's congenital amaurosis sponsored by Applied Genetics Technologies; and Drs. Hauswirth and Jacobson, being coinventors on a patent (20070077228) held by the University of Pennsylvania, the University of Florida, and Cornell University on “a method for treating or retarding the development of blindness” (Dr. Jacobson has waived all claims to any financial benefit as a coinventor on the patent).
No other potential conflict of interest relevant to this letter was reported.
5 References1
den Hollander AI ,Roepman R ,Koenekoop RK ,Cremers FP . Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008;27:391-419
CrossRef | Web of Science | Medline2
Bainbridge JWB ,Smith AJ ,Barker SS , et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-2239
Full Text | Web of Science | Medline3
Maguire AM ,Simonelli F ,Pierce EA , et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248
Full Text | Web of Science | Medline4
Hauswirth WW ,Aleman TS ,Kaushal S , et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-990
CrossRef | Web of Science | Medline5
Cideciyan AV ,Aleman TS ,Boye SL , et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008;105:15112-15117
CrossRef | Web of Science | Medline
- Citing Articles (29)
Citing Articles
1
Crystel Bonnet, Aziz El-Amraoui. (2012) Usher syndrome (sensorineural deafness and retinitis pigmentosa). Current Opinion in Neurology 25:1, 42-49
CrossRef2
Aravind Asokan, David V Schaffer, R Jude Samulski. (2012) The AAV Vector Toolkit: Poised at the Clinical Crossroads. Molecular Therapy
CrossRef3
Can Xu, Yunliang Sun, Yunfeng Wang, Yan Yan, Zhengjie Shi, Lei Chen, Han Lin, Shunli Lü, Maoling Zhu, Changqing Su, Zhaoshen Li. (2012) CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Letters
CrossRef4
Chen Liu, Bin Sun, Ni An, Weifeng Tan, Lu Cao, Xiangji Luo, Yong Yu, Feiling Feng, Bin Li, Mengchao Wu, Changqing Su, Xiaoqing Jiang. (2011) Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Molecular Oncology 5:6, 545-554
CrossRef5
Samantha L Ginn, Ian E Alexander. (2011) Gene therapy: Progress in childhood disease. Journal of Paediatrics and Child Healthno-no
CrossRef6
Marc S. Weinberg, Thomas J. McCown. (2011) Current prospects and challenges for epilepsy gene therapy. Experimental Neurology
CrossRef7
Jared N. Silver, Melissa Elder, Thomas Conlon, Pedro Cruz, Amy J. Wright, Arun Srivastava, Terence R. Flotte. (2011) Recombinant Adeno-Associated Virus-Mediated Gene Transfer for the Potential Therapy of Adenosine Deaminase-Deficient Severe Combined Immune Deficiency. Human Gene Therapy 22:8, 935-949
CrossRef8
C Mussolino, M della Corte, S Rossi, F Viola, U Di Vicino, E Marrocco, S Neglia, M Doria, F Testa, R Giovannoni, M Crasta, M Giunti, E Villani, M Lavitrano, M L Bacci, R Ratiglia, F Simonelli, A Auricchio, E M Surace. (2011) AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Therapy 18:7, 637-645
CrossRef9
José-Alain Sahel. (2011) Spotlight on childhood blindness. Journal of Clinical Investigation 121:6, 2145-2149
CrossRef10
Barbara Langer, Klaus Cichutek. (2011) Klinische Anwendung der Gentherapie. Bisherige Erfahrungen und Zukunft. Pharmazie in unserer Zeit 40:3, 254-262
CrossRef11
Federico Mingozzi, Katherine A. High. (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Reviews Genetics 12:5, 341-355
CrossRef12
Mathias Fradot, Volker Busskamp, Valérie Forster, Thérèse Cronin, Thierry Léveillard, Jean Bennett, José-Alain Sahel, Botond Roska, Serge Picaud. (2011) Gene Therapy in Ophthalmology: Validation on Cultured Retinal Cells and Explants from Postmortem Human Eyes. Human Gene Therapy 22:5, 587-593
CrossRef13
Hélène Cwerman-Thibault, José-Alain Sahel, Marisol Corral-Debrinski. (2011) Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations. Journal of Inherited Metabolic Disease 34:2, 327-344
CrossRef14
Linda Stein, Kamolika Roy, Lei Lei, Shalesh Kaushal. (2011) Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis. Expert Opinion on Biological Therapy 11:3, 429-439
CrossRef15
Crystel Bonnet, M'hamed Grati, Sandrine Marlin, Jacqueline Levilliers, Jean-Pierre Hardelin, Marine Parodi, Magali Niasme-Grare, Diana Zelenika, Marc Délépine, Delphine Feldmann, Laurence Jonard, Aziz El-Amraoui, Dominique Weil, Bruno Delobel, Christophe Vincent, Hélène Dollfus, Marie-Madeleine Eliot, Albert David, Catherine Calais, Jacqueline Vigneron, Bettina Montaut-Verient, Dominique Bonneau, Jacques Dubin, Christel Thauvin, Alain Duvillard, Christine Francannet, Thierry Mom, Didier Lacombe, Françoise Duriez, Valérie Drouin-Garraud, Marie-Françoise Thuillier-Obstoy, Sabine Sigaudy, Anne-Marie Frances, Patrick Collignon, Georges Challe, Rémy Couderc, Mark Lathrop, José-Alain Sahel, Jean Weissenbach, Christine Petit, Françoise Denoyelle. (2011) Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis. Orphanet Journal of Rare Diseases 6:1, 21
CrossRef16
Artur V. Cideciyan. (2010) Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Progress in Retinal and Eye Research 29:5, 398-427
CrossRef17
Kamolika Roy, Linda Stein, Shalesh Kaushal. (2010) Ocular Gene Therapy: An Evaluation of Recombinant Adeno-Associated Virus-Mediated Gene Therapy Interventions for the Treatment of Ocular Disease. Human Gene Therapy 21:8, 915-927
CrossRef18
Anthony A Vugler. (2010) PROGRESS TOWARD THE MAINTENANCE AND REPAIR OF DEGENERATING RETINAL CIRCUITRY. Retina 30:7, 983-1001
CrossRef19
J Pang, S E Boye, B Lei, S L Boye, D Everhart, R Ryals, Y Umino, B Rohrer, J Alexander, J Li, X Dai, Q Li, B Chang, R Barlow, W W Hauswirth. (2010) Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Therapy 17:7, 815-826
CrossRef20
Marie Csete. (2010) Translational prospects for human induced pluripotent stem cells. Regenerative Medicine 5:4, 509-519
CrossRef21
A. M. Komaromy, J. J. Alexander, J. S. Rowlan, M. M. Garcia, V. A. Chiodo, A. Kaya, J. C. Tanaka, G. M. Acland, W. W. Hauswirth, G. D. Aguirre. (2010) Gene therapy rescues cone function in congenital achromatopsia. Human Molecular Genetics 19:13, 2581-2593
CrossRef22
Alexa N. Bramall, Alan F. Wright, Samuel G. Jacobson, Roderick R. McInnes. (2010) The Genomic, Biochemical, and Cellular Responses of the Retina in Inherited Photoreceptor Degenerations and Prospects for the Treatment of These Disorders. Annual Review of Neuroscience 33:1, 441-472
CrossRef23
Fansheng Kong, Wensheng Li, Xia Li, Qinxiang Zheng, Xufeng Dai, Xiangtian Zhou, Sanford L. Boye, William W. Hauswirth, Jia Qu, Ji-jing Pang. (2010) Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Experimental Eye Research 90:5, 546-554
CrossRef24
Francesca Simonelli, Albert M Maguire, Francesco Testa, Eric A Pierce, Federico Mingozzi, Jeannette L Bennicelli, Settimio Rossi, Kathleen Marshall, Sandro Banfi, Enrico M Surace, Junwei Sun, T Michael Redmond, Xiaosong Zhu, Kenneth S Shindler, Gui-Shuang Ying, Carmela Ziviello, Carmela Acerra, J Fraser Wright, Jennifer Wellman McDonnell, Katherine A High, Jean Bennett, Alberto Auricchio. (2010) Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration. Molecular Therapy 18:3, 643-650
CrossRef25
Yi Lai, Yongping Yue, Dongsheng Duan. (2010) Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb. Molecular Therapy 18:1, 75-79
CrossRef26
Albert M Maguire, Katherine A High, Alberto Auricchio, J Fraser Wright, Eric A Pierce, Francesco Testa, Federico Mingozzi, Jeannette L Bennicelli, Gui-shuang Ying, Settimio Rossi, Ann Fulton, Kathleen A Marshall, Sandro Banfi, Daniel C Chung, Jessica IW Morgan, Bernd Hauck, Olga Zelenaia, Xiaosong Zhu, Leslie Raffini, Frauke Coppieters, Elfride De Baere, Kenneth S Shindler, Nicholas J Volpe, Enrico M Surace, Carmela Acerra, Arkady Lyubarsky, T Michael Redmond, Edwin Stone, Junwei Sun, Jennifer Wellman McDonnell, Bart P Leroy, Francesca Simonelli, Jean Bennett. (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. The Lancet 374:9701, 1597-1605
CrossRef27
Frans PM Cremers, Rob WJ Collin. (2009) Promises and challenges of genetic therapy for blindness. The Lancet 374:9701, 1569-1570
CrossRef28
Elie Dolgin. (2009) Colour blindness corrected by gene therapy. Nature
CrossRef29
(2009) The Digest. Human Gene Therapy 20:9, 920-920
CrossRef
